Latest Myopia News

CooperVision to Present Myopia Management Research at BCLA Conference

June 8, 2021

SAN RAMON, Calif. — CooperVision is slated to present research findings from more than 20 investigations at the upcoming British Contact Lens Association Virtual Clinical Conference and Exhibition, which will be held virtually on June 13 and 14.

Among the range of information covering the contact lens industry’s evolution will be new data and insights on understanding children’s acceptance of innovative optical interventions for slowing the progression of myopia.

CooperVision will present three myopia management-related presentations:

Myopia Progression and Slit-Lamp Findings in Children: MiSight 1 day Clinical Trial (Lumb E, et al.) offers additional insights from the oft-cited long-term study of the CooperVision soft contact lenses for slowing the progression of myopia, which are currently worn by children in more than two dozen countries. At the conclusion of year six, both weekend and weekday wearing time had increased to nearly 13 and 14 hours, respectively, compared to the minimum recommendation of 10 hours per day. This suggests that the children happily adapted to MiSight 1 day—an essential element in ensuring compliance.

Acceptance is also the focus of Wearing Experience with a Novel Myopia Management Spectacle Lens Technology (Rappon J, et al.), which evaluated SightGlass Vision Diffusion Optics Technology with children as young as age six. Superb vision and an excellent wearing experience were demonstrated through year one of the ongoing multi-year study. The unique lenses, which have been shown to reduce myopia progression, displayed high wearing compliance, high-quality distance and near vision (measured objectively and subjectively), and high satisfaction in children liking their appearance and loving their glasses.

Evaluation of Children in the Netherlands Fitted with Custom-Made Ortho-K Contact Lenses (van Hees-Teuben K, et al.) considered the myopia control efficacy observed among children in controlled studies with the real-world practice environment. Three-year tracking of Procornea DreamLite night lenses, which recently earned a CE Mark for slowing the progression of myopia, demonstrated near-stable refraction and axial length growth among 40 children. The evaluation also revealed good subjective acceptance for comfort and handling, vision and happiness with the lenses, supporting that myopic children can readily adapt to treatment.


To Top